肿瘤学中的限制性净治疗获益
本文介绍限制性净治疗获益(rNTB)这一临床意义明确且易处理的疗效估计量,适用于至少一个带时间限制的生存终点的随机试验。模拟研究显示rNTB估计在右删失下无偏,可纳入最小临床相关差异阈值及毒性,并给出PRODIGE、Checkmate-066和Checkmate-067试验的应用示例。
要点
- rNTB是带时间限制的净治疗获益估计量,不依赖比例风险等参数假设。
- 模拟研究显示rNTB估计在右删失下无偏,并可纳入最小临床相关差异阈值。
- 纳入毒性可提高检验功效(当实验组毒性更低时),rNTB检验功效在实验组生存更长且毒性更低时增加。
核心结论
- rNTB是描述和检验治疗效应的有趣替代方法,尤其在非比例风险或需平衡获益与安全性的情形下。
- rNTB可调整以考虑短期或长期生存差异以及一个或多个优先结局。
研究设计与样本
- 模拟研究,测试延迟治疗效应、最小临床相关差异阈值、限制时间值以及将疗效和毒性同时纳入rNTB定义等因素对rNTB值、估计和功效的影响。
- 在右删失下以偏倚评估rNTB,并比较rNTB衍生统计检验与对数秩检验的功效。
- 提供PRODIGE、Checkmate-066和Checkmate-067试验的应用示例。
主要发现
- rNTB估计即使在右删失情况下也无偏。
- rNTB可用于估计新治疗的获益/风险比,例如同时考虑生存和毒性并纳入多个优先结局。
- 在有删失时,估计的rNTB比NTB更易解释,因为后者本质上依赖于随访时长。
- 当实验治疗毒性更低时,纳入毒性增加检验功效。
- 当实验治疗与更长生存和更低毒性相关时,rNTB衍生检验功效增加,且在存在治愈率或延迟治疗效应时可能增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The restricted Net Treatment Benefit (rNTB) is a clinically meaningful and tractable estimand of the overall treatment effect assessed in randomized trials when at least one survival endpoint with time restriction is used. Its interpretation does not rely on parametric assumptions such as proportional hazards, can be estimated without bias even in the presence of independent right-censoring, and can include a prespecified threshold of minimal clinically relevant difference. To demonstrate that the rNTB, corresponding to the NTB during a predefined time interval, is a meaningful and adaptable measure of treatment effect in clinical trials. METHODS: In this simulation study, we tested the impact on the rNTB value, estimation, and power of several factors including the presence of a delayed treatment effect, minimal clinically relevant difference threshold value, restriction time value, and the inclusion of both efficacy and toxicity in the rNTB definition. The impact of right censoring on rNTB was assessed in terms of bias. rNTB-derived statistical tests and log rank (LR) tests were compared in terms of power. RESULTS: RNTB estimates are unbiased even in case of right-censoring. rNTB may be used to estimate the benefit/risk ratio of a new treatment, for example, taking into account both survival and toxicity and include several prioritized outcomes. The estimated rNTB is much easier to interpret in this context compared to NTB in the presence of censoring since the latter is intrinsically dependent on the follow-up duration. Including toxicity increases the test power when the experimental treatment is less toxic. rNTB-derived test power increases when the experimental treatment is associated with longer survival and lower toxicity and might increase in the presence of a cure rate or a delayed treatment effect. Case applications on the PRODIGE, Checkmate-066, and Checkmate-067 trials are provided. CONCLUSIONS: RNTB is an interesting alternative to describe and test the treatment's effect in a clear and understandable way in case of restriction, particularly in scenarios with nonproportional hazards or when trying to balance benefit and safety. It can be tuned to take into consideration short- or long-term survival differences and one or more prioritized outcomes.
引用
- Piffoux M, Ozenne B, De Backer M, et al. Restricted Net Treatment Benefit in oncology. J Clin Epidemiol. 2024. PMID: 38570079. doi:10.1016/j.jclinepi.2024.111340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。